Clinical Trials
13 trialsNCT02195973 2026-02-09
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Completed
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT07068568 2025-07-16
BCC-Sonidegib
Federico II University
Completed
NCT03434262 2024-05-31
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
NCT02086552 2021-12-03
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01485744 2020-08-04
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01954355 2019-12-06
LDE225 and Paclitaxel in Solid Tumors
Swiss Cancer Institute
Phase 1 Completed
NCT02129101 2019-10-30
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Phase 1 Completed
NCT02111187 2019-03-07
LDE225
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT01579929 2017-08-17
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01529450 2017-01-16
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Stanford University
Phase NA Completed